ONOsot Nerapusee

Osot Nerapusee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Osot Nerapusee has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A scoping review of authorisation pathway for COVID - 19 vaccines among selected countries

    by Supapitch Suphap, Parnnaphat Luksameesate, Osot Nerapusee, Puree Anantachoti

    In response to COVID-19 pandemic, NRAs implemented expedited mechanisms such as EUAs and CMAs, relying on international bodies, to authorize vaccines. Documenting these authorization pathways across countries informs NRAs and strengthens future pandemic responses. Existing studies on COVID-19 vaccine approvals are limited, underscoring the need for a comprehensive review. This study aimed to explore approval pathways, investigate supporting strategies, and review times for COVID-19 vaccines. A scoping review was conducted, covering countries with stringent regulatory authorities or countries with significant COVID-19 vaccine manufacturing or rapid rollout. Searches using terms such as ‘approval process’ and ‘COVID-19 vaccine’ were performed in electronic databases and on official regulatory authority websites. Countries without authorization information or with language barriers were excluded. Data on vaccine authorization processes including supporting strategies, submission criteria, and approval timelines were extracted and analyzed using content and comparative regulatory analysis. Twenty-four regulatory pathways from 20 countries were identified, categorized as ‘emergency use authorization’ (EUA) (n = 10), ‘conditional marketing authorization’ (CMA) (n = 8), and “temporary authorization’ (TA) (n = 6). Twelve new pathways were created by 11 countries, with four countries using two pathways each for different pandemic stages. Common requirements for vaccine approval included good manufacturing practice (GMP) (92%), benefit-risk evaluation (86%), and unmet need (83%). Supporting strategies like ‘rolling submission’ (85%) and ‘pre-submission meeting’ (85%) facilitated and fasten the approval process. Non-high-income countries favored the ‘reliance’ strategy, while high-income countries engaged in regulatory networking. The FDA and EMA were the most referenced agencies. Review times for the first COVID-19 vaccines ranged from 10 to 84 days, significantly faster (3-27 times) than standard review times. Despite different regulatory pathways, all countries approved the first COVID-19 vaccine quickly. International collaboration was crucial in accelerating approval times. The COVID-19 pandemic positively stimulated global preparedness for serious pandemics.


  • Open Access

    Financial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study

    by Manthana Laichapis, Rungpetch Sakulbumrungsil, Khunjira Udomaksorn, Nusaraporn Kessomboon, Osot Nerapusee, Charkkrit Hongthong, Sitanun Poonpolsub

    Background: Thailand’s pharmaceutical industry is prioritizing innovation and self-reliance through the development of incrementally modified drugs (IMDs), particularly sustained-release dosage forms. However, the financial feasibility of IMD development remains underexplored. Objective: This study evaluates the financial feasibility of developing sustained-release IMDs in Thailand, focusing on costs, timelines, and investment requirements to inform strategic decision-making. Methods: A mixed methods approach was used, combining literature reviews, expert interviews, and financial modeling. Two scenarios were analyzed: (1) only development (phase I) and (2) full clinical trials (phase I to III). Sensitivity analysis was used to assess the impact of key variables on financial feasibility. Results: The research and development (R&D) process for sustained-release IMDs takes 7 years for phase I–only development, costing US $1.46‐3.09 million, and 11 years for full clinical trials, costing US $18.60‐20.23 million. Process validation batches accounted for 60% of costs in phase I–only scenarios, while clinical trials represented 70% of costs in full clinical trial scenarios. The annual income required for a 5-year payback period ranged from US $0.20‐1.80 million (phase I only) to US $3.01‐27.11 million (full trials). Shorter R&D durations and longer payback periods substantially improved feasibility. Conclusions: Developing sustained-release IMDs in Thailand involves substantial costs and extended timelines but offers a lower-risk alternative to new chemical entities. Strategic investments, efficient R&D processes, and supportive policies are essential to enhance feasibility and alignment with national goals of innovation and self-reliance.


  • Open Access

    Authors’ Response to Peer Reviews of “Financial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study”

    by Manthana Laichapis, Rungpetch Sakulbumrungsil, Khunjira Udomaksorn, Nusaraporn Kessomboon, Osot Nerapusee, Charkkrit Hongthong, Sitanun Poonpolsub

    This is the author(s)’ responses to peer review reports related to MS ID#65978

  • Open Access

    The evolution of outpatient dispensing services in Thailand’s hospitals: what has been done and where are we heading?

    by Trisak Chetsurakarn, Nattapong Khansai, Alisara Sangviroon Sujarit, Osot Nerapusee, Sanguan Lerkiatbundit, Puree Anantachoti

    Outpatient pharmacy dispensing services in Thailand require patients to fill prescriptions at hospital pharmacies for reimbursement. This study explored hospital outpatient dispensing services in Thailand before, during, and after the COVID-19 pandemic. Characteristics of most frequently used alternative services were described. The study further explored the challenges and enablers associated with continuation of alternative hospital outpatient dispensing services. This study utilised a telephone survey targeting management-level hospital pharmacists from various hospital types and sizes. A stratified random sample of 305 hospitals was drawn from 1,471 hospitals. Data was collected using a validated semi-structured interview questionnaire between June-October 2022. Descriptive statistics and content analysis were used for data analysis. Data from 189 public hospitals were analysed. Before COVID-19, 38.6% of hospitals implemented at least one type of alternative outpatient dispensing service to reduce overcrowding and waiting times. During the pandemic, 97.4% of hospitals implemented alternative services with drug delivery service being most popular among large hospitals. Primary hospitals utilised other services such as subdistrict hospital network which better suited their contexts. Post-pandemic, many large-sized hospitals planned to continue drug delivery service. Enabling factors included reducing overcrowding and supporting patients, while challenges were workload and patient willingness to pay. The COVID-19 pandemic has redefined outpatient dispensing services in Thailand, making drug delivery a new norm. Hospitals should evaluate current situations and adjust criteria and workflows to sustain these services.


  • Open Access

    Dosage form selection using price function of prediction market

    by Charkkrit Hongthong, Rungpetch Sakulbumrungsil, Nusaraporn Kessomboon, Sitanun Poonpolsub, Osot Nerapusee, Manthana Laichapis, Khunjira Udomaksorn

    Backgrounds A prediction market (PM) is a process for predicting future events by gathering knowledge from participants. Researchers applied PM concept to predict the new dosage form, the industry may be able to produce incrementally modified drugs (IMDs) in the future. Methods The PM process started with building a PM based on the market scoring rule, which is a mechanism that automatically adjusts prices through the calculation of the price function by the market maker. Analysis of data according to the PM process. Since March 19, 2022, participants in Thailand’s pharmaceutical industry have been using online Zoom sessions to engage in purposive selection for trading contracts, following the submission of consent forms. Qualitative data analysis will be conducted using thematic analysis. Results A total of 28 participants. In the first round, participants were interested in investing in the sustained release, orodispersible tablet, and soft gelatin capsule. The second round was after receiving the dosage form information. Participants adjusted their investments to sustained release, orodispersible tablets, and nasal spray, by choosing to invest in the nasal spray dosage form because the company has the potential to produce. In the final round to confirm investment results the top three participants were sustained release, orodispersible tablet, and nasal spray dosage form. Conclusion The dosage forms industry is expected to produce IMDs in the future, including sustained release, orodispersible tablets, and nasal spray.


  • Open Access

    Scoping Review of International Experience of a Dedicated Fund to Support Patient Access to Cancer Drugs: Policy Implications for Thailand

    by Parnnaphat Luksameesate, Osot Nerapusee, Chanthawat Patikorn, Puree Anantachoti

    Background: Access to high-cost cancer drugs is an unsolved problem globally. The dedicated drugs fund is attractive and feasible. This study reviewed currently implemented dedicated drugs fund worldwide to inform policy implications for Thailand. Methods: A scoping review was conducted to identify countries currently implementing dedicated funds for cancer drugs. We searched electronic databases, PubMed and Embase, from 2010 to May 2021, Google and Google Scholar in August 2021, and government websites up to April 2022. The structure, management, cost containment strategies, and impact of dedicated funds were summarized and compared across the identified countries and Thailand. Results: Out of 218 nations, Hong Kong, England, and Italy have established dedicated cancer drugs fund, primarily funded by their governments. Funds in England and Italy operate within annual budget limits. Hong Kong relies on an endowment fund. In England and Italy, pharmaceutical companies contribute proportionally to cover overspending as per risk-sharing agreements, while cost-sharing is not required. Hong Kong implements cost-sharing based on a patient's family income. England and Italy employ a parallel pathway, utilizing the same drug selection committee to determine whether innovative drugs belong in the regular pharmaceutical benefits package or the dedicated drugs fund. Hong Kong follows a sequential pathway, allowing drugs to be considered for the dedicated funds after a negative decision. These countries use the fund for 5-11 years, making administrative adjustments to ensure sustainability. Conclusion: The dedicated drugs fund is an effective strategy to improve access to non-reimbursable high-cost drugs in Thailand. Robust evaluation of the fund itself and funded drugs are recommended for policymakers’ better decision-making. Learning from other countries can offer promising solutions. Health insurers need to balance providing cancer treatments with overall system preparedness.


  • Open Access

    Feasibility study of sustained release dosage forms for incrementally modified drug by domestics pharmaceutical industry in Thailand

    by Charkkrit Hongthong, Rungpetch Sakulbumrungsil, Khunjira Udomaksorn, Sitanun Poonpolsub, Osot Nerapusee, Manthana Laichapis, Nusaraporn Kessomboon

    Background Incrementally modified drugs (IMDs) are anticipated to improve drug efficacy and compliance. Compared to new chemical entities, the research and development costs for IMDs are lower. The domestics industry currently focuses on manufacturing both generic and new generic drugs. To promote the growth of the industry, it is crucial to investigate the feasibility of developing IMDs. Methods This necessitates evaluating all five aspects, including needs, market, scientific, technological, and regulatory feasibility from January to December 2022. A mixed methods approach, combining literature review and in-depth interviews conducted online via Zoom. Qualitative data analysis will be performed through thematic analysis. Results Needs: medical needs, six out of seven physicians expressed a preference for sustained release (SR). The domestics industry is actively engaged in the research and development of SR as well. Market feasibility: The compound annual growth rate for SR in 2019 was found to be 3.97 percent, SR encompassing all nine of the 14-drug group. Scientific feasibility is not a concern as the industry has the capability to develop drugs. Technological feasibility: The IMDs technology readiness level is at level 4 (high level). The manufacturing of SR utilizes a matrix technique, membrane system, and pellets. Regulatory feasibility: Although have registration guidelines for IMDs, no industry has successfully registered IMDs yet. Conclusions SR has demonstrated feasibility for IMDs development in all aspects except for the challenging issue of drug registration.


  • Open Access

    Efficacy and safety of cannabidiol for the treatment of canine osteoarthritis: a systematic review and meta-analysis of animal intervention studies

    by Chanthawat Patikorn, Osot Nerapusee, Kumpanart Soontornvipart, Kanta Lawonyawut, Kachapong Musikpodok, Kanisorn Waleethanaphan, Puree Anantachoti

    Introduction: Canine osteoarthritis (OA) is a degenerative disease with chronic inflammation of internal and external joint structures in dogs.Cannabisspp. contains cannabidiol (CBD), a substance known for various potential indications, such as pain relief and anti-inflammatory in various types of animals, including dogs with OA. As CBD is increasingly in the spotlight for medical use, we aimed to perform a systematic review and meta-analysis to evaluate the efficacy and safety of CBD in treating canine OA.Methods: We searched PubMed, Embase, Scopus, and CAB Direct for animal intervention studies investigating the effects of CBD for canine OA from database inception until February 28, 2023. Study characteristics and findings were summarized. A risk of bias in the included studies was assessed. Meta-analyses were performed using a random-effects model to estimate the effects of CBD on pain scores (0–10), expressed as mean difference (MD) and 95% confidence interval (95% CI). Certainty of evidence was assessed using GRADE.Results: Five articles were included, which investigated the effects of CBD in 117 dogs with OA. All studies were rated as having a high risk of bias. CBD products varied substantially, i.e., oral full-spectrum CBD oil in four studies, and isolated CBD oil and liposomal CBD oil in another study. Treatment duration varied from 4–12 weeks. Meta-analyses of three studies found that, in dogs with OA, treatment with oral full-spectrum CBD oil may reduce pain severity scores (MD; −0.60, 95% CI; −1.51 to 0.31,I2= 45.64%,p = 0.19) and pain interference scores (MD; −1.52, 95% CI; −3.84 to 0.80,I2= 89.59%,p = 0.20) but the certainty of evidence was very low. CBD is generally considered safe and well-tolerated in the short-run, with few mild adverse events observed, such as vomiting and asymptomatic increase in alkaline phosphatase level.Conclusion: CBD is considered safe for treating canine OA. CBD may reduce pain scores, but the evidence is very uncertain to conclude its clinical efficacy. High-quality clinical trials are needed to further evaluate the roles of CBD in canine OA.